AAV-based in vivo gene therapy for neurological disorders

1. Janson, C. et al. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum. Gene Ther. 13, 1391–1412 (2002).

   Article 
   CAS 
   PubMed 

   Google Scholar 

2. Leone, P. et al. Long-term follow-up after gene therapy for Canavan disease. Sci. Transl. Med. 4, 165ra163 (2012).

   Article 
   PubMed 
   PubMed Central 

   Google Scholar 

3. Cavazzana, M., Bushman, F. D., Miccio, A., André-Schmutz, I. & Six, E. Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat. Rev. Drug. Discov. 18, 447–462 (2019).

   Article 
   CAS 
   PubMed 

   Google Scholar 

4. Kinsella, J. L. et al. Ex-vivo autologous stem cell gene therapy clinical trial for mucopolysaccharidosis type IIIA: trial in progress-NCT04201405. Blood 136, 15–16 (2020).

   Article 

   Google Scholar 

5. Gentner, B. et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N. Engl. J. Med. 385, 1929–1940 (2021).

   Article 
   CAS 
   PubMed 

   Google Scholar 

6. Fumagalli, F. et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet 399, 372–383 (2022).

   Article 
   CAS 
   PubMed 
   PubMed Central 

   Google Scholar 

7. Eichler, F. et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 377, 1630–1638 (2017).

   Article 
   CAS 
   PubMed 
   PubMed Central 

   Google Scholar 

8. Charlesworth, C. T., Hsu, I., Wilkinson, A. C. & Nakauchi, H. Immunological barriers to haematopoietic stem cell gene therapy. Nat. Rev. Immunol. 12, 719–733 (2022).

   Article 

   Google Scholar 

9. Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. & Gao, G. Viral vector platforms within the gene therapy landscape. Signal. Transduct. Target. Ther. 6, 1–24 (2021).

   Article 

   Google Scholar 

10. Sung, Y. K. & Kim, S. Recent advances in the development of gene delivery systems. Biomater. Res. 23, 1–7 (2019).

    Article 

    Google Scholar 

11. Atchison, R. W., Casto, B. C. & Hammon, W. M. Adenovirus-associated defective virus particles. Science 149, 754–756 (1965).

    Article 
    CAS 
    PubMed 

    Google Scholar 

12. Flotte, T. R. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 11, 805–810 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

13. Duque, S. et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187–1196 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

14. Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59–65 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar 

15. Gao, G. et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381–6388 (2004).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

16. Yao, Y. et al. Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood–brain barrier in rodents and primates. Nat. Biomed. Eng. 6, 1257–1271 (2022). This paper uses a rational design approach to identify two new AAV9 variants that can cross the BBB.

    Article 
    CAS 
    PubMed 

    Google Scholar 

17. Kumar, S. R. et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nat. Methods 17, 541–550 (2020).

    Article 
    PubMed Central 

    Google Scholar 

18. Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106–115 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

19. Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172–1179 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

20. Chen, X. et al. Engineered AAVs for non-invasive functional transgene expression in rodent and non-human primate central and peripheral nervous systems. Neuron 110, 2242–2257 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

21. Meyer, N. L. & Chapman, M. S. Adeno-associated virus (AAV) cell entry: structural insights. Trends Microbiol. 30, 432–451 (2021).

    Article 
    PubMed 

    Google Scholar 

22. Summerford, C. & Samulski, R. J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438–1445 (1998).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

23. Kaludov, N., Brown, K. E., Walters, R. W., Zabner, J. & Chiorini, J. A. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75, 6884–6893 (2001).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

24. Wu, Z., Miller, E., Agbandje-McKenna, M. & Samulski, R. J. α2,3 and α2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80, 9093–9103 (2006).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

25. Shen, S., Bryant, K. D., Brown, S. M., Randell, S. H. & Asokan, A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J. Biol. Chem. 286, 13532–13540 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

26. Riyad, J. M. & Weber, T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 28, 683–696 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

27. Penaud-Budloo, M. et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J. Virol. 82, 7875–7885 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

28. Dalwadi, D. A. et al. AAV integration in human hepatocytes. Mol. Ther. 29, 2898–2909 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

29. McCarty, D. M., Monahan, P. E. & Samulski, R. J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8, 1248–1254 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

30. McCarty, D. M. et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112–2118 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

31. Chen, X. et al. Biodistribution of adeno-associated virus gene therapy following cerebrospinal fluid-directed administration. Hum. Gene Ther. 34, 94–111 (2023). This paper conducts a comprehensive literature review to compare the biodistribution of AAV from different intra-CSF administration routes.

    Article 
    CAS 
    PubMed 

    Google Scholar 

32. Bharucha-Goebel, D. et al. O.10 First-in-human intrathecal gene transfer study for giant axonal neuropathy: preliminary review of long-term efficacy and safety. Neuromuscul. Disord. 32, S94 (2022).

    Article 

    Google Scholar 

33. Bailey, R. M., Armao, D., Nagabhushan Kalburgi, S. & Gray, S. J. Development of intrathecal AAV9 gene therapy for giant axonal neuropathy. Mol. Ther. Methods Clin. Dev. 9, 160–171 (2018). This paper is the first study to show the safety and efficacy of using intrathecal lumbar administration route for delivering gene therapy to treat neurological disorders.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

34. Mendell, J. R. et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017). This paper reports clinical data from the clinical trial for SMA, the first gene therapy approved for a neurological disorder.

    Article 
    CAS 
    PubMed 

    Google Scholar 

35. Al-Zaidy, S. A. & Mendell, J. R. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr. Neurol. 100, 3–11 (2019).

    Article 
    PubMed 

    Google Scholar 

36. Burghes, A. H. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10, 597–609 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

37. Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285–298 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

38. Niethammer, M. et al. Gene therapy reduces Parkinson’s disease symptoms by reorganizing functional brain connectivity. Sci. Transl. Med. 10, eaau0713 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

39. Ciesielska, A. et al. Anterograde axonal transport of AAV2–GDNF in rat basal ganglia. Mol. Ther. 19, 922–927 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

40. Okada, S. & O’Brien, J. S. Generalized gangliosidosis: β-galactosidase deficiency. Science 160, 1002–1004 (1968).

    Article 
    CAS 
    PubMed 

    Google Scholar 

41. Gray-Edwards, H. L. et al. Novel biomarkers of human GM1 gangliosidosis reflect the clinical efficacy of gene therapy in a feline model. Mol. Ther. 25, 892–903 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

42. Gross, A. L. et al. Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis. Brain 145, 655–669 (2022).

    Article 
    PubMed 

    Google Scholar 

43. Taghian, T. et al. Real-time MR tracking of AAV gene therapy with βgal-responsive MR probe in a murine model of GM1-gangliosidosis. Mol. Ther. Methods Clin. Dev. 23, 128–134 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

44. Mussche, S. et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum. Gene Ther. 24, 209–219 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

45. Fu, H. et al. Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9–hSGSH gene delivery. Mol. Ther. Methods Clin. Dev. 3, 16036 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

46. Woodley, E. et al. Efficacy of a bicistronic vector for correction of sandhoff disease in a mouse model. Mol. Ther. Methods Clin. Dev. 12, 47–57 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

47. Rosenberg, J. B. et al. AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer’s disease. Hum. Gene Ther. Clin. Dev. 29, 24–47 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

48. Flotte, T. R. et al. AAV gene therapy for Tay–Sachs disease. Nat. Med. 28, 251–259 (2022). This paper summarizes clinical findings from the first AAV gene therapy clinical trial treating two children with Tay–Sachs disease.

    Article 
    CAS 
    PubMed 

    Google Scholar 

49. Taghian, T. et al. A safe and reliable technique for CNS delivery of AAV vectors in the cisterna magna. Mol. Ther. 28, 411–421 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

50. Flotte, T. R. et al. Phase 1/2 clinical trial of combined bilateral intrathalamic/intracisternal/intrathecal delivery of a rAAVrh8 vector in infantile and juvenile Tay-Sachs and sandhoff disease: report of ongoing studies. In ESGCT 29th Annual Congress in collaboration with BSGCT Edinburgh, UK, October 11–14, 2022 Abstracts Vol. 33, A71 (Mary Ann Liebert, 2022).

51. Garcia-Sanz, P., Aerts, J. M. F. G. & Moratalla, R. The role of cholesterol in α-synuclein and lewy body pathology in GBA1 Parkinson’s disease. Mov. Disord. 36, 1070–1085 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

52. Li, D., Zhang, J. & Liu, Q. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci. 45, 401–414 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

53. Sucunza, D. et al. Glucocerebrosidase gene therapy induces α-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques. Int. J. Mol. Sci. 22, 4825 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

54. Sheehan, P. et al. PR001 gene therapy improved phenotypes in models of Parkinson’s disease with GBA1 mutation: molecular and cell biology/endosomal–lysosomal dysfunction. Alzheimer’s Dement. 16, e043614 (2020).

    Article 

    Google Scholar 

55. Tardieu, M. et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 25, 506–516 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar 

56. Tardieu, M. et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurol. 16, 712–720 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar 

57. Gougeon, M.-L. et al. Cell-mediated immunity to NAGLU transgene following intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome. Front. Immunol. 12, 655478 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

58. Sondhi, D. et al. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Sci. Transl. Med. 12, eabb5413 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

59. Castle, M. J. et al. Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer’s disease identifies a need for improved vector delivery. Hum. Gene Ther. 31, 415–422 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

60. Kantor, B., McCown, T., Leone, P. & Gray, S. J. Clinical applications involving CNS gene transfer. Adv. Genet. 87, 71–124 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar 

61. Hyland, K. & Clayton, P. Aromatic amino acid decarboxylase deficiency in twins. J. Inherit. Metab. Dis. 13, 301–304 (1990).

    Article 
    CAS 
    PubMed 

    Google Scholar 

62. Tai, C.-H. et al. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol. Ther. 30, 509–518 (2022). This paper summarizes the clinical findings from 26 patients with AADC deficiency receiving AAV gene therapy treatment through IPa administration, which led to the approval of this treatment by the EMA.

    Article 
    CAS 
    PubMed 

    Google Scholar 

63. Baek, R. C. et al. AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS ONE 5, e13468 (2010).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

64. Cearley, C. N. & Wolfe, J. H. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci. 27, 9928–9940 (2007).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

65. Pearson, T. S. et al. Gene therapy for aromatic l-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2–AADC to midbrain dopaminergic neurons. Nat. Commun. 12, 4251 (2021). This paper summarizes clinical findings from the first AAV gene therapy clinical trial using a magnetic resonance-guided IPa gene delivery approach.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

66. Salegio, E. A. et al. Feasibility of targeted delivery of AAV5–GFP into the cerebellum of nonhuman primates following a single convection-enhanced delivery infusion. Hum. Gene Ther. 33, 86–93 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

67. Yazdan-Shahmorad, A. et al. Widespread optogenetic expression in macaque cortex obtained with MR-guided, convection enhanced delivery (CED) of AAV vector to the thalamus. J. Neurosci. Methods 293, 347–358 (2018).

    Article 
    PubMed 

    Google Scholar 

68. Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M. & Sah, D. W. Y. Gene therapy for neurological disorders: progress and prospects. Nat. Rev. Drug. Discov. 17, 641 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

69. Ravina, B. et al. Intraputaminal AADC gene therapy for advanced Parkinson’s disease: interim results of a phase 1b trial [abstract]. Hum. Gene Ther. 28, OR12 (2017).

    Google Scholar 

70. Davidson, B. L. et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl Acad. Sci. USA 97, 3428–3432 (2000).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

71. Christine, C. W. et al. Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial. Neurology 98, e40–e50 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

72. Luo, J. et al. Subthalamic GAD gene therapy in a Parkinson’s disease rat model. Science 298, 425–429 (2002).

    Article 
    CAS 
    PubMed 

    Google Scholar 

73. Niethammer, M. et al. Long-term follow-up of a randomized AAV2–GAD gene therapy trial for Parkinson’s disease. JCI Insight 2, e90133 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

74. Rocco, M. T. et al. Long-term safety of MRI-guided administration of AAV2–GDNF and gadoteridol in the putamen of individuals with Parkinson’s disease. Mol. Ther. 30, 3632–3638 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

75. Bartus, R. T. et al. Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV–neurturin (CERE-120) in Parkinson’s disease. Neurobiol. Aging 34, 35–61 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

76. Bartus, R. T. et al. Safety/feasibility of targeting the substantia nigra with AAV2–neurturin in Parkinson patients. Neurology 80, 1698–1701 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

77. Gray, S. J., Woodard, K. T. & Samulski, J. R. Viral vectors and delivery strategies for CNS gene therapy. Ther. Deliv. 1, 517–534 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar 

78. Heller, G. J. et al. Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease. Mol. Ther. 29, 1883–1902 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

79. Chen, X. et al. AAV9/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease. J. Clin. Invest. 132, e146286 (2022). This paper presents a case showing how a preclinical study is translated into a clinical trial, with all the data that are required for an investigational new drug (IND) application included.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

80. Kishimoto, T. K. & Samulski, R. J. Addressing high dose AAV toxicity—‘one and done’or ‘slower and lower’? Expert. Opin. Biol. Ther. 22, 1067–1071 (2022).

    Article 
    PubMed 

    Google Scholar 

81. Gray, S. J., Nagabhushan Kalburgi, S., McCown, T. J. & Jude Samulski, R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 20, 450–459 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

82. Samaranch, L. et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23, 382–389 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

83. Kondratov, O. et al. A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system. Mol. Ther. 29, 2806–2820 (2021). This paper compares the biodistribution of 29 different AAV serotypes in the CNS of NHPs when administered through IPa and intra-CSF administration routes.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

84. Gray, S. J. Timing of gene therapy interventions: the earlier, the better. Mol. Ther. 24, 1017–1018 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

85. Rashnonejad, A. et al. Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice. Mol. Ther. 27, 2123–2133 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

86. Lowes, L. P. et al. Impact of age and motor function in a phase 1/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr. Neurol. 98, 39–45 (2019).

    Article 
    PubMed 

    Google Scholar 

87. Chu, W. S. & Ng, J. Immunomodulation in administration of rAAV: preclinical and clinical adjuvant pharmacotherapies. Front. Immunol. 12, 858 (2021).

    Article 

    Google Scholar 

88. Barnes, C., Scheideler, O. & Schaffer, D. Engineering the AAV capsid to evade immune responses. Curr. Opin. Biotech. 60, 99–103 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

89. Bertolini, T. B. et al. Effect of CpG depletion of vector genome on CD8⁺ T cell responses in AAV gene therapy. Front. Immunol. 12, 672449 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

90. Wright, J. F. Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare? Mol. Ther. 28, 701–703 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

91. Pan, X. et al. Rational engineering of a functional CpG-free ITR for AAV gene therapy. Gene Ther. 29, 333–345 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

92. Muhuri, M. et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J. Clin. Invest. 131, e143780 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

93. Kofoed, R. H. et al. Transgene distribution and immune response after ultrasound delivery of rAAV9 and PHP.B to the brain in a mouse model of amyloidosis. Mol. Ther. Methods Clin. Dev. 23, 390–405 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

94. Ciesielska, A. et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol. Ther. 21, 158–166 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

95. Hadaczek, P. et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum. Gene Ther. 20, 225–237 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

96. Samaranch, L. et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol. Ther. 22, 329–337 (2014). This paper is the first to demonstrate that using AAV to deliver a non-self protein, but not a self protein, may trigger neural immune responses in NHPs.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

97. Ramsingh, A. I. et al. Sustained AAV9-mediated expression of a non-self protein in the CNS of non-human primates after immunomodulation. PLoS ONE 13, e0198154 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

98. Ling, Q., Rioux, M., Hu, Y., Lee, M. & Gray, S. J. Adeno-associated viral vector serotype 9-based gene replacement therapy for SURF1-related leigh syndrome. Mol. Ther. Methods Clin. Dev. 23, 158–168 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

99. Dell’Agnello, C. et al. Increased longevity and refractoriness to Ca²⁺-dependent neurodegeneration in Surf1 knockout mice. Hum. Mol. Genet. 16, 431–444 (2007).

    Article 
    PubMed 

    Google Scholar 

100. Quadalti, C. et al. SURF1 knockout cloned pigs: early onset of a severe lethal phenotype. Biochim. Biophys. Acta 1864, 2131–2142 (2018).

     Article 
     CAS 
     PubMed Central 

     Google Scholar 

101. Bradbury, A. M. et al. Krabbe disease successfully treated via monotherapy of intrathecal gene therapy. J. Clin. Invest. 130, 4906–4920 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

102. Karumuthil‐Melethil, S. et al. Intrathecal administration of AAV/GALC vectors in 10–11‐day‐old twitcher mice improves survival and is enhanced by bone marrow transplant. J. Neurosci. Res. 94, 1138–1151 (2016).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

103. Li, M. & Belmonte, I.J.C. Organoids — preclinical models of human disease. N. Engl. J. Med. 380, 569–579 (2019).

     Article 
     PubMed 

     Google Scholar 

104. Gorman, G. S. et al. Mitochondrial diseases. Nat. Rev. Dis. Prim. 2, 1–22 (2016).

     Google Scholar 

105. Reynaud-Dulaurier, R. et al. Gene replacement therapy provides benefit in an adult mouse model of Leigh syndrome. Brain 143, 1686–1696 (2020).

     Article 
     PubMed 

     Google Scholar 

106. Silva-Pinheiro, P., Cerutti, R., Luna-Sanchez, M., Zeviani, M. & Viscomi, C. A single intravenous injection of AAV–PHP.B–hNDUFS4 ameliorates the phenotype of Ndufs4^−/− mice. Mol. Ther. Methods Clin. Dev. 17, 1071–1078 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

107. Pereira, C. V. et al. Myopathy reversion in mice after restauration of mitochondrial complex I. EMBO Mol. Med. 12, e10674 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

108. Meo, I. D., Marchet, S., Lamperti, C., Zeviani, M. & Viscomi, C. AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome. Gene Ther. 24, 661–667 (2017).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

109. Abrams, A. J. et al. Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. Nat. Genet. 47, 926–932 (2015).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

110. Janer, A. et al. SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol. Med. 8, 1019–1038 (2016).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

111. Charlesworth, G. et al. SLC25A46 mutations underlie progressive myoclonic ataxia with optic atrophy and neuropathy. Mov. Disord. 31, 1249–1251 (2016).

     Article 
     CAS 
     PubMed 

     Google Scholar 

112. Hammer, M. B. et al. SLC25A46 mutations associated with autosomal recessive cerebellar ataxia in North African families. Neurodegener. Dis. 17, 208–212 (2017).

     Article 
     CAS 
     PubMed 

     Google Scholar 

113. Yang, L. et al. Systemic administration of AAV–Slc25a46 mitigates mitochondrial neuropathy in Slc25a46^−/− mice. Hum. Mol. Genet. 29, 649–661 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

114. Vila-Julia, F. et al. Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosides. EBioMedicine 62, 103133 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

115. Di Meo, I. et al. Effective AAV‐mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol. Med. 4, 1008–1014 (2012).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

116. Chadderton, N. et al. Intravitreal delivery of AAV–NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy. Eur. J. Hum. Genet. 21, 62–68 (2013).

     Article 
     CAS 
     PubMed 

     Google Scholar 

117. Koilkonda, R. D. et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol. 132, 409–420 (2014).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

118. Torres-Torronteras, J. et al. Long-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. Hum. Gene Ther. 29, 708–718 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

119. Fountain, M. D. & Schaaf, C. P. Prader–Willi syndrome and Schaaf–Yang syndrome: neurodevelopmental diseases intersecting at the MAGEL2 gene. Diseases 4, 2 (2016).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

120. Queen, N. J. et al. Hypothalamic AAV–BDNF gene therapy improves metabolic function and behavior in the Magel2-null mouse model of Prader–Willi syndrome. Mol. Ther. Methods Clin. Dev. 27, 131–148 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

121. Zeier, Z. et al. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther. 16, 1122–1129 (2009).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

122. Arsenault, J. et al. FMRP expression levels in mouse central nervous system neurons determine behavioral phenotype. Hum. Gene Ther. 27, 982–996 (2016).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

123. Gholizadeh, S., Arsenault, J., Xuan, I. C. Y., Pacey, L. K. & Hampson, D. R. Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice. Neuropsychopharmacology 39, 3100–3111 (2014).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

124. Turner, T. J., Zourray, C., Schorge, S. & Lignani, G. Recent advances in gene therapy for neurodevelopmental disorders with epilepsy. J. Neurochem. 157, 229–262 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

125. Davidson, B. L. et al. Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders. Mol. Ther. 30, 2416–2428 (2022). This paper summarizes the discussions and presentations of ‘Gene-Based Therapeutics for Rare Genetic Neurodevelopmental Psychiatric Disorders’, a National Institute of Mental Health-sponsored workshop held in January 2021.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

126. Prabhakar, S. et al. Long-term therapeutic efficacy of intravenous AAV-mediated hamartin replacement in mouse model of tuberous sclerosis type 1. Mol. Ther. Methods Clin. Dev. 15, 18–26 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

127. Gao, Y. et al. Gene replacement ameliorates deficits in mouse and human models of cyclin-dependent kinase-like 5 disorder. Brain 143, 811–832 (2020).

     Article 
     PubMed 

     Google Scholar 

128. Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome. Taysha https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-initiation-clinical-0 (2022).

129. Sinnett, S. E., Boyle, E., Lyons, C. & Gray, S. J. Engineered microRNA-based regulatory element permits safe high-dose mini MECP2 gene therapy in Rett mice. Brain 144, 3005–3019 (2021). This paper shows the development of a self-regulatory gene therapy approach using endogenous miRNAs.

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

130. Luoni, M. et al. Whole brain delivery of an instability-prone Mecp2 transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome. eLife 9, e52629 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

131. Heeroma, J. H. et al. Episodic ataxia type 1 mutations differentially affect neuronal excitability and transmitter release. Dis. Model. Mech. 2, 612–619 (2009).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

132. Qiu, Y. et al. On-demand cell-autonomous gene therapy for brain circuit disorders. Science 378, 523–532 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

133. Judson, M. C. et al. Dual-isoform hUBE3A gene transfer improves behavioral and seizure outcomes in Angelman syndrome model mice. JCI Insight 6, e144712 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

134. Ogiwara, I. et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J. Neurosci. 27, 5903–5914 (2007).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

135. Tanenhaus, A. et al. Cell-selective AAV-mediated SCN1A gene regulation therapy rescues mortality and seizure phenotypes in a dravet syndrome mouse model and is well tolerated in non-human primates. Hum. Gene Ther. 33, 579–597 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

136. Howden, S., Voullaire, L. & Vadolas, J. The transient expression of mRNA coding for Rep protein from AAV facilitates targeted plasmid integration. J. Gene Med. 10, 42–50 (2008).

     Article 
     CAS 
     PubMed 

     Google Scholar 

137. Dalwadi, D. A. et al. Liver injury increases the incidence of HCC following AAV gene therapy in mice. Mol. Ther. 29, 680–690 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

138. Donsante, A. et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477–477 (2007).

     Article 
     CAS 
     PubMed 

     Google Scholar 

139. Nguyen, G. N. et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat. Biotechnol. 39, 47–55 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

140. Day, J. W. et al. Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy. Drug. Saf. 44, 1109–1119 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

141. Guillou, J. et al. Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy. Blood Adv. 6, 4266–4270 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

142. Hordeaux, J. et al. Adeno-associated virus-induced dorsal root ganglion pathology. Hum. Gene Ther. 31, 808–818 (2020). This paper analyses potential factors leading to DRG pathology from AAV gene therapy by compiling data from 33 non-clinical studies in NHPs.

     Article 
     CAS 
     PubMed 

     Google Scholar 

143. Buss, N. et al. Characterization of AAV-mediated dorsal root ganglionopathy. Mol. Ther. Methods Clin. Dev. 24, 342–354 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

144. Mueller, C. et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N. Engl. J. Med. 383, 151–158 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

145. Hordeaux, J. et al. microRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci. Transl. Med. 12, eaba9188 (2020).

     Article 
     CAS 
     PubMed 

     Google Scholar 

146. Kayani, S, et al. Preliminary safety data of a phase 1 first in-human clinical trial support the use of high dose intrathecal AAV9/CLN7 for the treatment of patients with CLN7 disease. Mol. Genet. Metabol. 135, S65 (2022).

     Article 

     Google Scholar 

147. Rosenberg, J. B. et al. Safety of direct intraparenchymal AAVrh.10-mediated central nervous system gene therapy for metachromatic leukodystrophy. Hum. Gene Ther. 32, 563–580 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

148. Agbandje-McKenna, M. & Kleinschmidt, J. AAV capsid structure and cell interactions. Methods Mol. Biol. 807, 47–92 (2011).

     Article 
     CAS 
     PubMed 

     Google Scholar 

149. Salganik, M. et al. Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J. Virol. 88, 1071–1079 (2014).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

150. Kanaan, N. M. et al. Rationally engineered AAV capsids improve transduction and volumetric spread in the CNS. Mol. Ther. Nucleic Acids 8, 184–197 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

151. Chan, Y. K. et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci. Transl. Med. 13, eabd3438 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

152. Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209 (2016).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

153. Hordeaux, J. et al. The neurotropic properties of AAV–PHP.B are limited to C57BL/6J mice. Mol. Ther. 26, 664–668 (2018). This paper demonstrates that AAV vectors can show different tropisms in different species.

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

154. Matsuzaki, Y. et al. Intravenous administration of the adeno-associated virus–PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci. Lett. 665, 182–188 (2018).

     Article 
     CAS 
     PubMed 

     Google Scholar 

155. Huang, Q. et al. Delivering genes across the blood–brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. PLoS ONE 14, e0225206 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

156. Lin, R. et al. Directed evolution of adeno-associated virus for efficient gene delivery to microglia. Nat. Methods 19, 976–985 (2022).

     Article 
     CAS 
     PubMed 

     Google Scholar 

157. Beharry, A. et al. The AAV9 variant capsid AAV-F mediates widespread transgene expression in nonhuman primate spinal cord after intrathecal administration. Hum. Gene Ther. 33, 61–75 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

158. Stanton, A. C. et al. Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS. Medicine 4, 31–50 (2022).

     Article 

     Google Scholar 

159. Mich, J. K. et al. Functional enhancer elements drive subclass-selective expression from mouse to primate neocortex. Cell Rep. 34, 108754 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

160. Powell, S. K., Rivera-Soto, R. & Gray, S. J. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov. Med. 19, 49–57 (2015).

     PubMed 
     PubMed Central 

     Google Scholar 

161. Jackson, K. L., Dayton, R. D., Deverman, B. E. & Klein, R. L. Better targeting, better efficiency for wide-scale neuronal transduction with the synapsin promoter and AAV-PHP.B. Front. Mol. Neurosci. 9, 116 (2016).

     PubMed 
     PubMed Central 

     Google Scholar 

162. Xie, J. et al. microRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol. Ther. 19, 526–535 (2011).

     Article 
     CAS 
     PubMed 

     Google Scholar 

163. Sidonio, R. F. Jr et al. Discussing investigational AAV gene therapy with hemophilia patients: a guide. Blood Rev. 47, 100759 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

164. Athey, J. et al. A new and updated resource for codon usage tables. BMC Bioinforma. 18, 391 (2017).

     Article 

     Google Scholar 

165. Mauro, V. P. & Chappell, S. A. A critical analysis of codon optimization in human therapeutics. Trends Mol. Med. 20, 604–613 (2014).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

166. Agashe, D., Martinez-Gomez, N. C., Drummond, D. A. & Marx, C. J. Good codons, bad transcript: large reductions in gene expression and fitness arising from synonymous mutations in a key enzyme. Mol. Biol. Evol. 30, 549–560 (2013).

     Article 
     CAS 
     PubMed 

     Google Scholar 

167. Spencer, P. S., Siller, E., Anderson, J. F. & Barral, J. M. Silent substitutions predictably alter translation elongation rates and protein folding efficiencies. J. Mol. Biol. 422, 328–335 (2012).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

168. Tsai, C.-J. et al. Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J. Mol. Biol. 383, 281–291 (2008).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

169. Zhou, J.-h et al. The effects of the synonymous codon usage and tRNA abundance on protein folding of the 3C protease of foot-and-mouth disease virus. Infect. Genet. Evol. 16, 270–274 (2013).

     Article 
     CAS 
     PubMed 

     Google Scholar 

170. Dominguez, E. et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681–693 (2011).

     Article 
     CAS 
     PubMed 

     Google Scholar 

171. Hordeaux, J. et al. Efficacy and safety of a Krabbe disease gene therapy. Hum. Gene Ther. 33, 499–517 (2022).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

172. Chand, D. et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J. Hepatol. 74, 560–566 (2021).

     Article 
     CAS 
     PubMed 

     Google Scholar 

173. Feldman, A. G. et al. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J. Pediatr. 225, 252–258 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

174. Hordeaux, J. et al. Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing iduronate-2-sulfatase in rhesus macaques. Mol. Ther. Methods Clin. Dev. 10, 68–78 (2018).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

175. Li, Y. et al. Enhanced efficacy and increased long-term toxicity of CNS-directed, AAV-based combination therapy for Krabbe disease. Mol. Ther. 29, 691–701 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

176. Boudreau, R. L., Spengler, R. M. & Davidson, B. L. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington’s disease. Mol. Ther. 19, 2169–2177 (2011).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

177. Boudreau, R. L., Martins, I. & Davidson, B. L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 17, 169–175 (2009).

     Article 
     CAS 
     PubMed 

     Google Scholar 

178. Franich, N. R. et al. AAV vector-mediated RNAi of mutant Huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease. Mol. Ther. 16, 947–956 (2008).

     Article 
     CAS 
     PubMed 

     Google Scholar 

179. Miniarikova, J. et al. AAV5–miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 24, 630–639 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

180. Meglio, M. uniQure receives DSMB recommendation to resume higher dosing of AMT-130 in huntington trial. Neurology Live https://www.neurologylive.com/view/uniqure-receives-dsmb-recommendation-resume-higher-dosing-amt-130-huntington-trial (2022).

181. Curtis, H. J., Seow, Y., Wood, M. J. & Varela, M. A. Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7. Nucleic Acids Res. 45, 7870–7885 (2017).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

182. Gaj, T., Guo, J., Kato, Y., Sirk, S. J. & Barbas, C. F. III Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 9, 805–807 (2012).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

183. Liu, J., Gaj, T., Patterson, J. T., Sirk, S. J. & Barbas, C. F. III Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS ONE 9, e85755 (2014).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

184. Carroll, D. Genome engineering with zinc-finger nucleases. Genetics 188, 773–782 (2011).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

185. Yamaguchi, T. et al. Aspects of gene therapy products using current genome-editing technology in Japan. Hum. Gene Ther. 31, 1043–1053 (2020).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

186. Newby, G. A. & Liu, D. R. In vivo somatic cell base editing and prime editing. Mol. Ther. 29, 3107–3124 (2021).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

187. Abudayyeh, O. O. et al. A cytosine deaminase for programmable single-base RNA editing. Science 365, 382–386 (2019).

     Article 
     CAS 
     PubMed 
     PubMed Central 

     Google Scholar 

188. Lubroth, P., Colasante, G. & Lignani, G. In vivo genome editing therapeutic approaches for neurological disorders: where are we in the translational pipeline? Front. Neurosci. 15, 632522 (2021).

     Article 
     PubMed 
     PubMed Central 

     Google Scholar 

Download references